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ABSTRACT
Background. After transplantation, cell-free deoxyribonucleic
acid (DNA) derived from the donor organ (ddcfDNA) can be
detected in the recipient’s circulation. We aimed to investigate
the role of plasma ddcfDNA as biomarker for acute kidney
rejection.
Methods. From 107 kidney transplant recipients, plasma
samples were collected longitudinally after transplantation
(Day 1 to 3months) within a multicentre set-up. Cell-free
DNA from the donor was quantiﬁed in plasma as a fraction
of the total cell-free DNA by next generation sequencing us-
ing a targeted, multiplex polymerase chain reaction-based
method for the analysis of single nucleotide polymorphisms.
Results. Increases of the ddcfDNA% above a threshold value of
0.88% were signiﬁcantly associated with the occurrence of epi-
sodes of acute rejection (P¼ 0.017), acute tubular necrosis
(P¼ 0.011) and acute pyelonephritis (P¼ 0.032). A receiver op-
erating characteristic curve analysis revealed an equal area un-
der the curve of the ddcfDNA% and serum creatinine of 0.64
for the diagnosis of acute rejection.
Conclusions. Although increases in plasma ddcfDNA% are
associated with graft injury, plasma ddcfDNA does not outper-
form the diagnostic capacity of the serum creatinine in the
diagnosis of acute rejection.
Keywords: acute kidney rejection, biomarker, donor-derived
cell-free DNA, kidney transplantation
INTRODUCTION
After renal transplantation, graft injury can be related to several
conditions including ischaemia/reperfusion, infection or acute
rejection [1]. Monitoring of the graft by measurement of serum
creatinine lacks specificity as increases in the serum creatinine
early after transplantation might be caused by intrinsic renal
processes but also by transient conditions such as volume de-
pletion or acute calcineurin inhibitor (CNI) toxicity [2].
Histological evaluation of a biopsy remains the gold standard
method to diagnose acute rejection, although there are limita-
tions of this procedure including its invasiveness, cost and
inter-observer variability [3, 4]. Furthermore, often, significant
graft damage is already present at the time of biopsy [5].
Therefore, there is an unmet clinical need of sensitive, non-
invasive markers that allow for the detection of acute rejection
in an early stage.
Donor-derived, cell-free deoxyribonucleic acid (ddcfDNA)
has been proposed as a candidate biomarker for graft injury after
solid organ transplantation as its release might be associated
with graft cell damage [6]. In heart and liver transplant recipients
with an acute rejection, increased plasma fractions of ddcfDNA
(proportion of circulating cell-free DNA that is donor-derived)
were observed compared with recipients with stable graft func-
tion, thereby suggesting a role for ddcfDNA as a biomarker of re-
jection [7, 8]. Currently, little is known about the role of
ddcfDNA as monitoring tool for ‘kidney’ allograft rejection.
VC The Author(s) 2019. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. 1
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The main aim of this study was to investigate if ddcfDNA
levels in kidney transplant recipients could serve as a possible
biomarker of renal allograft rejection. Therefore, we designed a
prospective, observational multicentre study in which
ddcfDNA was quantified in serial plasma samples of renal
transplant recipients.
MATERIALS AND METHODS
Study design
The study was approved by the Ethics committees of the
Antwerp University Hospital (file number 14/30/308) and the
Ghent University Hospital (file number 2014-1200). The study
was in accordance with the Helsinki Declaration (2013). Adult
patients who received kidney transplantation were enrolled in a
multicentre, prospective, observational clinical study at the
Antwerp University Hospital and the Ghent University
Hospital between October 2014 and March 2017 after provid-
ing a written informed consent. The Antwerp University
Hospital included all consecutive patients who received kidney
transplantation, except for patients with a history of non-
kidney transplantation, multi-organ transplant recipients and
patients who preferred not to participate in the study. In addi-
tion to these exclusion criteria, patients who were referred from
general hospitals were not included at the University Hospital
of Ghent to ensure a complete follow-up of 3 months.
Sample collection
After renal transplantation, blood samples were collected in
Cell-Free DNA BCTVR collecting tubes (Streck, NE, USA) at 10
time points: Day 1, Day 3, Week 1, Week 2, Week 3, Week 4,
Week 6, Week 8, Week 10 and Month 3. Additional blood sam-
ples were collected simultaneously with a protocol biopsy pro-
cedure and during hospital admission for a rise in serum
creatinine and/or the performance of an indication biopsy.
From each recipient, a whole blood EDTA sample was collected
before transplantation to isolate genomic DNA (gDNA). From
each deceased donor, gDNA was provided by the
Histocompatibility and Immunogenetic Laboratory (HILA,
Belgian Red Cross Flanders, Mechelen, Belgium) and from each
living donor, a whole blood EDTA sample or buccal swab
(Isohelix, Kent, UK) was collected after a written informed con-
sent to isolate gDNA.
Cell-free DNA and gDNA extraction
Within 2 days after collection, blood samples were centri-
fuged following a 2-step centrifugation protocol (1600g for
10min and 3200g for 20min at room temperature) to remove
the cells. Within 6months of storage at80C, plasma samples
were thawed at room temperature and cell-free DNA was
extracted as previously described [9]. gDNAwas extracted from
EDTA blood samples or buccal swabs by a standard salting-out
procedure [10] or using a Buccalyse DNA extraction kit
(Isohelix), respectively.
Quantification of ddcfDNA
Fractions of ddcfDNA in plasma samples were quantified as
a proportion of total circulating cell-free DNA using the
Sequido assay (Multiplicom, Agilent Technologies). This assay
enables a targeted amplification of 1027 single nucleotide poly-
morphisms containing amplicons for subsequent next genera-
tion sequencing. For specifications of the assay workflow, we
refer to Gielis et al. [9].
Histological evaluation of renal biopsies
All protocol and indication biopsies were evaluated centrally
and blinded from the results of ddcfDNA% measurements by a
single experienced nephropathologist (A. Dendooven, MD,
PhD) at the Antwerp University Hospital according to the
Banff 2013 classification of allograft rejection [11, 12].
Clinical data collection and definitions
Histological diagnoses. Acute rejection episodes were diag-
nosed based on the clinicopathological diagnosis of an indica-
tion or protocol biopsy, thereby including borderline treated
rejection episodes, episodes of T-cell-mediated rejection
(TCMR) (Banff I, II, III), antibody-mediated rejection (ABMR)
or combined TCMR and ABMR rejection episodes. The diag-
nosis of acute tubular necrosis was made based on histology,
and defined in the absence of acute rejection.
Clinical diagnoses. Delayed graft function was defined as a
need of dialysis within the first week after transplantation [13].
Treated urinary tract infections were registered, including cases
of symptomatic lower urinary tract infections and pyelonephri-
tis (chills, fever and positive urinary culture with/without posi-
tive blood cultures). A BK viral (BKV) infection was defined as
a progressive increase in viral DNA load [diagnosed with poly-
merase chain reaction (PCR)] requiring an adjustment of the
maintenance immunosuppressive treatment. A cytomegalovi-
rus (CMV) infection was defined as a progressive increase in vi-
ral DNA load (PCR) requiring antiviral treatment in a
therapeutic dose. Episodes of oedema or fluid retention were
registered when intravenous diuretic treatment was required.
Pre-renal acute kidney injury was defined as an increase in se-
rum creatinine with a decrease in serum creatinine following
fluid treatment. CNI-induced serum creatinine increases were
diagnosed when they resulted in lowering of the CNI dose.
Statistical analysis
Sample size calculation. According to the actual incidences,
15% of kidney transplant recipients develop a graft rejection.
Based on a 0.9–2.8% increase in ddcfDNA in the rejection
group compared with the stable group with a standard devia-
tion of 1.2% in the stable group and 1.8% in the rejection group
[14, 15] and a power of 80%, at least 54 patients needed to be in-
cluded in the stable group and at least 10 patients needed to be
included in the rejection group using the t-statistic test for com-
paring the mean of a continuous measurement in two
samples (https://www.stat.ubc.ca/rollin/stats/ssize/n2.html).
We additionally included 40% more patients to compensate for
dropouts.
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Plasma ddcfDNA% increases. Increased plasma ddcf
DNA% measurements were defined as any ddcfDNA% value
exceeding the 0.88% threshold that was previously established
in stable kidney transplant patients [9], while values equal to or
below were considered as stable ddcfDNA% measurements. As
ddcfDNA% decreases exponentially after transplantation to
reach a stable ddcfDNA threshold value on average 10 days af-
ter transplantation [9], we only analysed ddcfDNA increases
from Day 10 onwards. We investigated the association of
ddcfDNA increases with adverse events that occurred 3 days
before to 7 days after the plasma ddcfDNA% measurement
with a Fisher’s exact test with an adjustment of the P-value
according to a Bonferroni correction for multiple testing.
A Spearman correlation analysis or analysis of variance was
performed to determine the correlation between clinical param-
eters and the ddcfDNA%, depending on the type of parameter.
ddcfDNA% as a biomarker of rejection. Plasma samples
that were collected 3 days before to 3 days after a renal biopsy
procedure and before any anti-rejection treatment were in-
cluded (further called ‘paired biopsies’). The association of the
individual Banff lesions with ddcfDNA% was established with a
Mann–Whitney U test. A receiver operating characteristic
curve (ROC) analysis was performed and the associated area
under the curve (AUC) values were calculated using the ROCR
package with either the ddcfDNA% or serum creatinine as a
predictive value. Confidence intervals (CIs) were calculated us-
ing a bootstrapping algorithm (pROC library, 100 iterations
and 90% CI). A DeLong test was performed to analyse differen-
ces between AUC values.
All analyses were performed in R (v3.2.4). Box plots were
generated using IBM SPSS Statistics (v.24).
RESULTS
Patients and samples
In total, 107 patients were enrolled into this study. The pre-
transplantation, donor and transplantation characteristics of
these recipients are shown in Table 1. Of these recipients, 1036
plasma samples were collected at 10 (84 recipients), 9 (16 recipi-
ents) and 8 (5 recipients) follow-up visits. In two recipients,
plasma sampling was ended after six visits because of a trans-
plant nephrectomy. Protocol biopsies were performed as
planned in 57 recipients between Week 10 and 3months.
A blood sample concomitant with the protocol biopsy was
available for 43 patients. Supplementary blood samples (total
number of 46) were drawn from 28 transplant recipients
hospitalized for acute graft dysfunction and/or indication
biopsy.
Increases in plasma ddcfDNA%
A total of 792 plasma samples were collected from Day 10
onwards after transplantation. Increased ddcfDNA fractions
were measured in 103 (13%) plasma samples. Samples from
one recipient were excluded from the analysis as this subject
never reached the 0.88% threshold value and remained at a
higher ddcfDNA% throughout the entire study follow-up with
median plasma ddcfDNA% of 1.76% (1.07–2.42%).
As shown in Table 2, increases of the plasma ddcfDNA%
were significantly associated with the occurrence of acute rejec-
tion (P¼ 0.017), pyelonephritis (P¼ 0.032) and episodes of
acute tubular necrosis (not related to acute rejection;
P¼ 0.011). In contrast, episodes of BKV or CMV infection,
symptomatic lower urinary tract infection, fluid retention, pre-
renal acute kidney injury or CNI-induced serum creatinine
increases were not significantly associated with increases in the
ddcfDNA fraction (Table 2).
Importantly, of the 103 ddcfDNA increases that were mea-
sured from Day 10 after transplantation onwards, 84 (82%)
increases could not be explained by the occurrence of acute rejec-
tion, pyelonephritis or acute tubular necrosis (Table 2). Plasma
ddcfDNA% did not correlate with kidney function [serum creati-
nine, r ¼0.04, P¼ 1.00; estimated glomerular filtration rate
(eGFR), r¼ 0.09, P¼ 0.16] nor with markers of inflammation [C-
reactive protein (CRP), r¼ 0.04, P¼ 1.00; neutrophils, r¼ 0.06,
P¼ 1.00] during the post-transplantation fromDay 10 onwards.
ddcfDNA as biomarker for acute rejection
ddcfDNA% and histological diagnoses. In total, 81 plasma
samples were analysed to investigate if the ddcfDNA%might be
useful to diagnose acute rejection after renal transplantation.
Paired biopsies were scored as normal [respectively, 41 (95.3%)
and 24 (63.2%) protocol and indication biopsies], acute rejec-
tion [respectively, 2 (4.7%) and 11 (28.9%) protocol and indica-
tion biopsies] or acute tubular necrosis [not in the context of
acute rejection, including 3 (7.9%) indication biopsies]. In
Figure 1, log-transformed plasma ddcfDNA fractions are
shown for different clinicopathological diagnoses. A median
ddcfDNA% of 0.42% (0.09–2.05%) was measured in plasma
samples collected paired with indication or protocol biopsies
showing no rejection neither acute tubular necrosis lesions
(n¼ 56), while the median plasma ddcfDNA% of the untreated
borderline rejection episodes (n¼ 9) was 0.55% (0.27–1.54%).
In recipients with a treated borderline rejection episode (n¼ 3),
plasma ddcfDNA% ranged from 0.36% to 0.56% with a median
ddcfDNA% of 0.48%. During four Banff IIA TCMR rejection
episodes (three recipients), a median ddcfDNA% of 0.42%
(0.29–1.19%) was measured. The plasma fractions of the
ddcfDNA exceeded the threshold value of 0.88% in all episodes
of combined TCMR and ABMR (n¼ 4) with median
ddcfDNA% of 6.97% (range 1.43–32.44%). In one recipient
with two episodes of ABMR, no increased plasma ddcfDNA
were measured, with median ddcfDNA% of 0.48% (range 0.37–
0.53%) throughout the post-transplantation period from Day
10 onwards. In this patient, however, dialysis was restarted at
the first day after transplantation and a diagnosis of primary
non-function led to a transplant nephrectomy 68days after
transplantation.
ddcfDNA% and individual Banff lesions. The presence of
peritubular capillaritis was significantly associated with
increased ddcfDNA% (P¼ 0.02) while histological signs of
interstitial inflammation (P¼ 0.13), tubulitis (P¼ 0.80),
Donor-derived cell-free DNA and acute rejection 3
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glomerulitis (P¼ 1.00) or vasculitis (P¼ 0.96) were not signifi-
cantly correlated. Furthermore, no significant association was
observed with C4d positivity (defined as focal or diffuse C4d
positivity on immunohistochemistry or diffuse positivity on im-
munofluorescence). No significant correlations were found be-
tween the ddcfDNA% and chronic Banff lesions (ci, ct, cv) or
mesangial matrix (mm) increase, nor with the presence of arte-
riolar hyalinosis (ah).
ROC analysis. An ROC analysis was performed to investi-
gate the test performance of the plasma ddcfDNA% to distin-
guish an acute rejection episode from a normal indication/
protocol biopsy or biopsy with borderline untreated rejection
episode or acute tubular necrosis (Figure 2). An AUC of 0.64
(90% CI 0.501–0.779) was observed, thereby showing a sensitiv-
ity and specificity of 38% and 85%, respectively, at a
ddcfDNA% of 0.88%. As shown in Figure 2, the measurement
of the ddcfDNA% did not outperform the serum creatinine
with an AUC of 0.64 (90% CI 0.499–0.781; P¼ 1.00).
Combining the two biomarkers might slightly improve the di-
agnostic capacity (AUC of 0.70; 90% CI 0.552–0.842) for the di-
agnosis of acute rejection.
Longitudinal analysis. In all subjects with a combined
TCMR and ABMR (n¼ 3), early increases in the ddcfDNA%
were observed before the clinical–histopathological diagnosis of
acute rejection. In these recipients, increases above the thresh-
old value of 0.88% were measured 1–9 days before histological
diagnosis. Rises in the serum creatinine were also present in this
period, except for one case in which increases in ddcfDNA%
were observed while serum creatinine remained stable. The
courses of the ddcfDNA% together with serum creatinine of the
three patients with a combined TCMR and ABMR are shown
in Figure 3.
DISCUSSION
This study was designed to investigate the usefulness of plasma
ddcfDNA for the detection of acute rejection after kidney trans-
plantation. We found that increases in ddcfDNA% above a
threshold value of 0.88% were associated with acute rejection,
and also with acute pyelonephritis and acute tubular necrosis in
the period from 10days to 3months after transplantation.
However, only 18% of the increases in ddcfDNA% could be
Table 1. Recipient, donor and transplantation characteristics of the entire
study cohort
Number of recipients 107
Antwerp University Hospital, n (%) 90 (84.1)
Ghent University Hospital, n (%) 17 (15.9)
Recipient characteristics (at transplantation)
Gender (male), n (%) 79 (73.8)
Age (years) 51 (18–71)
Diabetes mellitus type II, n (%) 16 (15.0)
Obesity (BMI 30 kg/m2), n (%) 26 (24.3)
Current smoking, n (%) 5 (4.7)
Chronic inﬂammatory disease/auto-
immune disease
37 (34.6)
Primary renal disease, n (%)
Glomerular disease 31 (29.0)
Chronic interstitial nephritis 12 (11.2)
Cystic disease 14 (13.1)
Renal vascular disease 15 (14.0)
Diabetes 4 (3.7)
Others 14 (13.1)
Not known 17 (15.9)
Renal replacement therapy before
transplantation, n (%)
101 (94.4)
Previous renal transplantation(s) 12 (11.2)
One, n (%) 6 (5.6)
Two, n (%) 6 (5.6)
PRA before transplantation, n (%)
0–4% 88 (82.2)
5–80% 12 (11.2)
>80% 7 (6.5)
Height (cm) 171.969.1
Weight (kg) 79.5615.9
BMI (kg/m2) 26.864.5
Donor characteristics n¼107
Donor type, n (%)
Living donor 13 (12.1)
Deceased donor 94 (87.9)
DBD 78 (72.9)
DCD 16 (15.0)
Donor age (years) 48 (16-72)
Height (cm) 173.368.9
Weight (kg) 78.4615.5
BMI (kg/m2) 25.5 (17.7–46.9)
Serum creatinine (mg/dL) 0.7 (0.2–1.5)
Donor–recipient compatibility characteristics
Number of HLA mismatches in HLA A and B, n (%)
0 8 (7.5)
1 24 (22.4)
2 50 (46.7)
3 23 (21.5)
4 2 (1.9)
Number of HLA mismatches in HLA DR, n (%)
0 28 (26.2)
1 73 (68.2)
2 6 (5.6)
Transplantation characteristics
Ischaemia times
Cold ischaemia time (h) 11.9 (6.1)
2nd warm ischaemia time (min) 30 (10–185)
Induction therapy [n (%)]
IL2-RA 62 (57.9)
ATG 45 (42.1)
Continued
Maintenance immunosuppressive treatment
Prednisolone, n (%) 107 (100.0)
MMF/azathioprin/everolimus, n (%) 101 (94.4)/2(1.9)/4 (3.7)
Tacrolimus/cyclosporin, n (%) 86 (80.4)/21 (19.6)
ATG, anti-thymocyte globulin; BMI, body mass index; DBD, donation after brain death;
DCD, donation after circulatory death; HLA, human leukocyte antigen; IL2-RA,
interleukin-2 receptor antagonist; MMF, mycophenolate mofetil; PRA, panel reactive
antibodies. Normally distributed continuous data are presented as a mean (6SD), not-
normally distributed data are presented as median (min–max).
4 E.M. Gielis et al.
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explained by the occurrence of these adverse events. Our data
further demonstrate that plasma ddcfDNA% does not outper-
form the serum creatinine for the diagnosis of acute rejection.
Increases in total cell-free DNA concentrations have been
previously reported in renal transplant recipients suffering
from local and systemic infection episodes and episodes of acute
tubular necrosis compared with recipients with stable graft
function [16], indicating that cell-free DNA can also be released
by the recipient cells during these complications. The observa-
tion of an increase in the ddcfDNA fraction during acute pyelo-
nephritis and acute tubular necrosis indicate that the release of
cell-free DNA from the graft exceeds the release of cell-free
DNA from the recipient’s cells during these events.
In the present study, increases in plasma ddcfDNA% in
patients with a combined ABMR-TCMRwere prominently pre-
sent in our study, with median fractions of 6.97%. In these
patients, increases above the threshold value of 0.88% were
measured 1–9 days before histological diagnosis. In a recently
published cross-sectional study [17], significantly higher
ddcfDNA%were measured in plasma of recipients showing his-
tological signs of acute or chronic active rejection compared
with recipients without signs of active rejection in the renal bi-
opsy. The presence of an ABMR resulted in higher plasma
ddcfDNA% (median 2.9%) compared with TCMR (Banff IB)
(median 1.2%). Plasma ddcfDNA% of patients with a TCMR
type IA did not significantly differ from the control group of bi-
opsies without evidence of active rejection (median 0.2% versus
0.3%). Using the same assay, Huang et al. found significantly in-
creased ddcfDNA% in plasma samples from patients with
ABMR and mixed ABMR compared with samples from
patients without rejection (median 1.4% versus 0.38%) or iso-
lated TCMR (0.27%) [18]. These phenotype-dependent
increases in the ddcfDNA% are in line with our findings, where
marked increases were observed during a combined rejection
phenotype.
In the present study, we implemented the genomic donor
and recipient DNA in the assay, so the precise ddcfDNA%
could be measured. In our study, ddcfDNA fractions of 32%
were measured in plasma samples from a patient with a mixed
TCMR and ABMR and of 54% in a recipient with acute tubular
necrosis. In contrast, in the study of Bloom et al., the gDNA of
the donor was not implemented in the assay used to quantify
donor fractions. Consequently, the upper limit of detection of
the assay was 25% [17, 19]. From our results, it became clear
that the plasma ddcfDNA% might increase to fractions >25%
in kidney transplant recipients.
As presented in Table 2, only a minority (18%) of the
ddcfDNA increases could be explained by the occurrence of ei-
ther acute rejection, acute pyelonephritis or acute tubular ne-
crosis in our cohort. Of course, these unexplained ddcfDNA
increases compromise the role of ddcfDNA as an adequate re-
jection monitoring tool.
Based on our ROC analysis (including samples collected
paired with a renal biopsy), the diagnostic capacity of the
ddcfDNA to diagnose rejection was rather poor with a sensitiv-
ity and specificity of 38% and 85%, respectively, at a threshold
of 0.88% ddcfDNA%. Furthermore, based on this sensitivity
and specificity, the positive predictive value of the assay is
expected to be poor and ranging from 22% to 39% according to
an acute rejection risk between 10% and 20%, respectively.
In kidney transplantation, using a threshold of 1%
ddcfDNA, Bloom et al. likewise reported a rather poor sensitiv-
ity but acceptable specificity of 59% and 85%, respectively, for
the discrimination of active rejection from no rejection (AUC
0.74) [17]. From these data, the authors concluded that a
plasma ddcfDNA% below 1% reflects the absence of an active
rejection and a ddcfDNA% exceeding 1% indicates a probability
of an active rejection. Using the same ddcfDNA threshold,
Huang et al. reported a sensitivity of 67.6% and specificity of
74.2% for the diagnosis of acute rejection [18]. It remains, how-
ever, remarkable that in both studies in approximately 25% of
the samples without active rejection, the ddcfDNA% was>1%.
With an AUC of 0.64, ddcfDNA% measurement does not
outperform the diagnostic capacity of the serum creatinine for
the distinction between rejection and no rejection in our study.
Bloom et al. reported an AUC of only 0.54 for the serum creati-
nine, which was weaker compared with the ddcfDNA test
Table 2. Overview of the number of samples with ddcfDNA% increases
and their association with adverse events
Increased
ddcfDNA
Adverse event P-value
Yes No
Acute rejection
Yes 9 94 0.017
No 15 667
Acute pyelonephritis
Yes 6 97 0.032
No 7 675
Acute tubular necrosis
Yes 4 99 0.011
No 1 681
BKV infection
Yes 1 102 1.00
No 11 671
CMV infection
Yes 9 94 0.29
No 25 657
Symptomatic low urinary tract infection
Yes 2 101 1.00
No 15 667
Fluid retention
Yes 4 99 0.54
No 8 674
Pre-renal acute kidney injury
Yes 3 100 1.00
No 16 666
CNI-induced serum creatinine increases
Yes 41 62 1.00
No 224 458
Increased ddcfDNA% were measured in 103 samples of a total amount of 785 samples
collected from 106 recipients from Day 10 onward after transplantation. Samples from
one recipient were excluded from the analysis as this subject never reached the 0.88%
threshold value and remained at a higher ddcfDNA% throughout the entire study fol-
low-up. Different cross-tables are shown for each reported adverse event. Signiﬁcant P-
values (P<0.05 with Fisher’s Exact test) are marked in bold.
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performance [17]. However, the design of these two studies was
different. While only samples paired with indication biopsy
procedures were included in the Bloom study, samples paired
with protocol biopsies were also included in our analysis.
Of course, future research is needed to investigate the
value of ddcfDNA as an add-on to other minimal
invasive biomarkers including donor-specific antibodies [20],
chemokines and microRNAs [21].
We did not find an association between increased plasma
ddcfDNA and the occurrence of BKV infection. In urine sam-
ples of renal transplant recipients, it was shown that increased
amounts of ddcfDNA are present in renal transplant recipients
with a BKV nephropathy compared with patients with stable
graft function [14]. In our study, plasma ddcfDNA% remained
below the threshold value in three cases of BKV nephropathy
(positive PCR accompanied with viral cytopathogenic changes
on biopsy). It might thus be possible that only urinary, not
plasma, ddcfDNA% reflects BKV infection.
In kidney transplant recipients, it has to be questioned
whether increased levels of ddcfDNA are related to impaired
kidney function rather than reflecting actual graft damage. In
analogy with our previous findings in the early post-
transplantation period [9], we did not observe a correlation be-
tween ddcfDNA% and kidney function (serum creatinine or
eGFR) between 10days and 3months after transplantation. It
has been shown that renal excretion is only a minor route of cell-
free DNA clearance [22], and total cell-free DNA levels do not
differ between patients with chronic kidney disease (CKD) and
healthy controls, nor between patients with different stages of
CKD [23–25]. Furthermore, in the present study, ddcfDNA was
measured as a fraction of the total circulating cell-free DNA, not
by quantification of absolute ddcfDNA levels. Wemay thus con-
clude that the ddcfDNA% is not related to the renal function.
It has to be considered that stable ddcfDNA values might differ
between kidney transplant recipients thereby reflecting graft qual-
ity or recipient or transplantation characteristics. However, in a re-
cent publication by our group, we did not find any significant
correlation between recipient, donor transplantation characteris-
tics and individual baseline ddcfDNA values in the same cohort of
patients [9].
FIGURE 1: Plasma ddcfDNA fractions and clinicopathological diagnosis. Box plots of plasma ddcfDNA%. The horizontal dashed line repre-
sents the ddcfDNA threshold value 0.88% determined in stable transplant recipients [9]. In one recipient with two episodes of ABMR, no in-
creased plasma ddcfDNA% were measured. In this patient, however, dialysis was restarted at the ﬁrst day after transplantation and a diagnosis
of primary non-function led to a transplant nephrectomy 68 days after transplantation. The plasma ddcfDNA fraction was increased during
three episodes of acute tubular necrosis (ATN). In one recipient with a ddcfDNA% increase to 53.64%, signs of acute calcineurin inhibitor tox-
icity were also present in the renal biopsy. In a second patient, ATN was diagnosed on an indication biopsy because of sudden anuria 12 days
after transplantation. After an initial decrease in the ddcfDNA fraction to 0.72% on Day 7, the ddcfDNA% increased to 3.00% during the epi-
sode of ATN. An indication biopsy was performed 10 days after transplantation in a third recipient because of a persistently poor kidney func-
tion. In this patient, also diagnosed with delayed graft function, a ddcfDNA% of 34.27% was measured on the ﬁrst day after transplantation.
The ddcfDNA% failed to decrease below threshold value within 10 days after transplantation, as the ddcfDNA% still amounted 3.42% at that
moment. Bord-T, borderline treated rejection episode; Bord-UT, borderline untreated rejection episode; NC, no changes on indication/proto-
col biopsy; n ¼ number of episodes; TCMR-ABMR, combined T-cell-mediated and antibody-mediated rejection episode.
6 E.M. Gielis et al.
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An important strength of this study is the longitudinal set-
up and the evaluation of the impact of different graft-associated
complications on the circulating ddcfDNA fraction. However,
due to the limited numbers of rejection subtypes, we cannot
make firm conclusions about the differences in plasma
ddcfDNA fractions between rejection phenotypes.
In summary, although increases in plasma ddcfDNA% are
associated with graft injury, plasma ddcfDNA does not outper-
form the diagnostic capacity of the serum creatinine in the diag-
nosis of acute rejection. Our data suggest that the use of this
ddcfDNA is limited by many unexplained increases that occur
in renal transplant recipients during longitudinal follow-up. At
this stage, the value of ddcfDNA as a rejection biomarker, there-
fore, seems rather limited.
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